Antibody-Targeted RNase Fusion Proteins (ImmunoRNases) for Cancer Therapy

Author(s): Jurgen Krauss, Michaela A.E. Arndt, Stefan Dubel, Susanna M. Rybak

Journal Name: Current Pharmaceutical Biotechnology

Volume 9 , Issue 3 , 2008

Become EABM
Become Reviewer
Call for Editor


Ribonucleases (RNases) of the superfamily A exhibit potent antineoplastic activity yet do not mediate appreciable immunogenicity or non-specific toxicity in both animal models and cancer patients. Ranpirnase (Onconase®), the first ribonuclease being evaluated as a therapeutic in humans, has progressed to phase III clinical trials in patients with unresectable mesothelioma. Conjugation of RNases to internalizing tumor-targeting monoclonal antibodies was shown to enhance specific cell killing by several orders of magnitude both in vitro and in animal models. In this review we describe the development and current status of genetically engineered 2nd generation immunoRNases as promising novel anticancer therapeutics.

Keywords: Rnase, Onconase®, immunoRNase, antibody-RNase fusion protein, immunotherapeutics

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [231 - 234]
Pages: 4
DOI: 10.2174/138920108784567317
Price: $65

Article Metrics

PDF: 11